ClinicalTrials.gov
public full text
Public Domain
Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients
This is an open-label randomised multicenter clinical study to compare immunogenicity of the drug products Insulin Glargine (Kalbe Farma) and Lantus (Sanofi -Aventis) in type 2 diabetes mellitus patients
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus#154848
- Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics#836829
- Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)#875948
- Insulin Glargine "All to Target" Trial#1114679
- Hubungan Hemoglobin dengan Kreatinin pada Penderita Diabetes Melitus: The Correlation Between Hemoglobin and Creatinine on Patients of Diabetes Mellitus#1004061
Record · ID 850213
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive